Welcome to our dedicated page for Spruce Biosciences news (Ticker: SPRB), a resource for investors and traders seeking the latest updates and insights on Spruce Biosciences stock.
Spruce Biosciences reports developments as a late-stage biopharmaceutical company focused on novel therapies for neurological disorders with significant unmet medical need. Its recurring news centers on tralesinidase alfa enzyme replacement therapy, or TA-ERT, for Sanfilippo Syndrome Type B (MPS IIIB), including clinical data presentations, FDA interactions and regulatory planning for the program.
Company updates also cover financial results, capital actions involving common stock and pre-funded warrants, investor conference participation, and additions to commercial leadership as Spruce builds capabilities around a potential rare-disease launch.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Spruce Biosciences, Inc. (NASDAQ: SPRB) reported significant developments including surpassing 50% enrollment in its CAHmelia-203 study for adult congenital adrenal hyperplasia (CAH) and a private placement financing of $53.6 million. The company entered an exclusive licensing agreement with Kaken Pharmaceutical for tildacerfont in Japan, receiving a $15 million upfront payment. With cash and investments of $79.1 million by year-end 2022, these funds extend the cash runway into 2025. The company also announced a net loss of $46.2 million for 2022, up from $42.3 million in 2021, amid rising R&D expenses to advance its clinical trials.
Spruce Biosciences (NASDAQ: SPRB), a biopharmaceutical company, announced that its CEO, Javier Szwarcberg, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 2:40 PM ET. The event will focus on Spruce's commitment to developing novel therapies for rare endocrine disorders with unmet medical needs, particularly their product candidate tildacerfont, aimed at treating classic congenital adrenal hyperplasia and a rare form of polycystic ovary syndrome. Interested stakeholders can access the live webcast here, with an archived version available for 30 days on the company’s investor relations website.